Jon Gitz Holler

Pathogen‐Specific Bloodstream Infections Associated With Tumour Necrosis Factor‐α Inhibitors, Vedolizumab and Ustekinumab in Inflammatory Bowel Disease: A Danish Nationwide Case‐Control Study 2010–2024

ABSTRACT Background Biologic drugs have substantially expanded treatment options for inflammatory bowel disease (IBD), but infection risk during exposure remains a concern. Aims To investigate the association between current use of tumour necrosis factor‐α inhibitors (TNFi), vedo...